Convergence Investment Partners LLC Boosts Stock Position in Prestige Consumer Healthcare Inc (NYSE:PBH)

Convergence Investment Partners LLC grew its stake in Prestige Consumer Healthcare Inc (NYSE:PBH) by 26.2% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 24,409 shares of the company’s stock after purchasing an additional 5,072 shares during the period. Convergence Investment Partners LLC’s holdings in Prestige Consumer Healthcare were worth $917,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently bought and sold shares of PBH. Norges Bank purchased a new position in Prestige Consumer Healthcare in the fourth quarter worth approximately $25,909,000. Macquarie Group Ltd. grew its position in Prestige Consumer Healthcare by 14.4% in the fourth quarter. Macquarie Group Ltd. now owns 2,001,580 shares of the company’s stock worth $81,065,000 after acquiring an additional 251,580 shares during the period. Nuveen Asset Management LLC grew its position in Prestige Consumer Healthcare by 18.9% in the first quarter. Nuveen Asset Management LLC now owns 1,346,190 shares of the company’s stock worth $49,379,000 after acquiring an additional 213,939 shares during the period. AQR Capital Management LLC grew its position in Prestige Consumer Healthcare by 1,051.3% in the first quarter. AQR Capital Management LLC now owns 137,265 shares of the company’s stock worth $5,007,000 after acquiring an additional 125,342 shares during the period. Finally, Grantham Mayo Van Otterloo & Co. LLC grew its position in Prestige Consumer Healthcare by 40.5% in the first quarter. Grantham Mayo Van Otterloo & Co. LLC now owns 434,500 shares of the company’s stock worth $15,937,000 after acquiring an additional 125,200 shares during the period.

Several research analysts recently weighed in on PBH shares. Zacks Investment Research lowered Prestige Consumer Healthcare from a “buy” rating to a “hold” rating and set a $42.00 price objective for the company. in a research report on Thursday, May 14th. Jefferies Financial Group lowered Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a research report on Tuesday, April 14th. ValuEngine cut Prestige Consumer Healthcare from a “sell” rating to a “strong sell” rating in a research note on Thursday, July 2nd. CIBC upped their price target on Prestige Consumer Healthcare from $86.00 to $88.00 and gave the stock a “neutral” rating in a research note on Tuesday, May 12th. Finally, TD Securities upped their price target on Prestige Consumer Healthcare from $90.00 to $97.00 and gave the stock a “hold” rating in a research note on Friday, July 24th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and two have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $65.43.

Shares of NYSE PBH traded down $0.39 during mid-day trading on Friday, hitting $37.19. The company had a trading volume of 357,825 shares, compared to its average volume of 315,282. The company has a market capitalization of $1.87 billion, a PE ratio of 13.38, a price-to-earnings-growth ratio of 3.11 and a beta of 0.80. The company has a debt-to-equity ratio of 1.50, a current ratio of 2.44 and a quick ratio of 1.67. Prestige Consumer Healthcare Inc has a 1-year low of $27.40 and a 1-year high of $46.12. The business’s 50-day simple moving average is $38.20 and its 200 day simple moving average is $39.22.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings data on Thursday, May 7th. The company reported $0.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.08. The business had revenue of $251.20 million for the quarter, compared to analysts’ expectations of $239.65 million. Prestige Consumer Healthcare had a return on equity of 13.33% and a net margin of 14.77%. The company’s revenue for the quarter was up 4.2% compared to the same quarter last year. During the same period last year, the firm earned $0.72 earnings per share. On average, analysts expect that Prestige Consumer Healthcare Inc will post 2.99 EPS for the current year.

In other news, CEO Ronald M. Lombardi sold 29,593 shares of the stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $40.00, for a total value of $1,183,720.00. Following the sale, the chief executive officer now directly owns 154,630 shares in the company, valued at $6,185,200. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 1.20% of the stock is currently owned by company insiders.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) healthcare and household cleaning products in North America, Australia, and internationally. It operates in three segments: North American OTC Healthcare, International OTC Healthcare, and Household Cleaning.

See Also: Stock Market – What is a circuit breaker?

Institutional Ownership by Quarter for Prestige Consumer Healthcare (NYSE:PBH)

Receive News & Ratings for Prestige Consumer Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prestige Consumer Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.